Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness

Jenna M. Young; Mike J. Schoonover; S. Logan Kembel; Jared D. Taylor; Anje G. Bauck; Lyndi L. Gilliam

doi:10.1016/j.vaa.2019.11.003

Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness

Jenna M. Young
, Mike J. Schoonover
, S. Logan Kembel
, Jared D. Taylor
, Anje G. Bauck
, Lyndi L. Gilliam

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Objective: To evaluate the analgesic effects of orally administered gabapentin on horses with chronic thoracic limb lameness. Study design: Randomized, crossover design. Animals: A total of 14 adult horses with chronic thoracic limb lameness. Methods: Following baseline measurement of lameness, horses were administered each of four treatments orally in grain: treatment G, gabapentin (20 mg kg^–1) twice daily for 13 doses; treatment F, firocoxib (171 mg once, then 57 mg once daily for six doses); treatment GF, gabapentin and firocoxib at previously stated doses and frequencies; or treatment C, grain only as a control. Treatments were administered in a randomized, crossover design, separated by 2 weeks. Subjective lameness score (SLS), inertial sensor vector sum (VS) calculations, peak vertical ground reaction force (PVGRF) measurements and vertical impulse (VI) calculations were determined immediately prior to each initial treatment dose and 2–4 hours after the final treatment dose for each treatment. Mean change in SLS, VS, PVGRF and VI for each treatment were compared among treatments. Results: The rank change in SLS of treatment GF was significantly greater than that of treatments C (p = 0.01) and G (p = 0.01) but not of treatment F (p = 0.08). No differences in VS (p = 0.4), PVGRF (p = 0.4) or VI (p = 0.1) were observed among treatments. Conclusions and clinical relevance: Gabapentin, as administered here, did not improve subjective or objective measures of lameness in horses with chronic thoracic limb musculoskeletal pain. Although subjective evaluation identified an improvement in lameness with treatment GF, it was not different from that observed with treatment F. Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses.

Original language	English (US)
Pages (from-to)	259-266
Number of pages	8
Journal	Veterinary anaesthesia and analgesia
Volume	47
Issue number	2
DOIs	https://doi.org/10.1016/j.vaa.2019.11.003
State	Published - Mar 2020
Externally published	Yes

Bibliographical note

Funding Information:
Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee , OK, USA. The firocoxib tablets were provided by Merial Inc., GA, USA.

Funding Information:
Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee, OK, USA. The firocoxib tablets were provided by Merial Inc. GA, USA.

Publisher Copyright:
© 2019 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia

Keywords

equine chronic lameness
firocoxib
gabapentin
pain management

Publisher link

10.1016/j.vaa.2019.11.003

Find It

Find It at U of M Libraries

Cite this

@article{fd9032fb5bbb42c5bfa1a98a3f83521c,

title = "Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness",

abstract = "Objective: To evaluate the analgesic effects of orally administered gabapentin on horses with chronic thoracic limb lameness. Study design: Randomized, crossover design. Animals: A total of 14 adult horses with chronic thoracic limb lameness. Methods: Following baseline measurement of lameness, horses were administered each of four treatments orally in grain: treatment G, gabapentin (20 mg kg–1) twice daily for 13 doses; treatment F, firocoxib (171 mg once, then 57 mg once daily for six doses); treatment GF, gabapentin and firocoxib at previously stated doses and frequencies; or treatment C, grain only as a control. Treatments were administered in a randomized, crossover design, separated by 2 weeks. Subjective lameness score (SLS), inertial sensor vector sum (VS) calculations, peak vertical ground reaction force (PVGRF) measurements and vertical impulse (VI) calculations were determined immediately prior to each initial treatment dose and 2–4 hours after the final treatment dose for each treatment. Mean change in SLS, VS, PVGRF and VI for each treatment were compared among treatments. Results: The rank change in SLS of treatment GF was significantly greater than that of treatments C (p = 0.01) and G (p = 0.01) but not of treatment F (p = 0.08). No differences in VS (p = 0.4), PVGRF (p = 0.4) or VI (p = 0.1) were observed among treatments. Conclusions and clinical relevance: Gabapentin, as administered here, did not improve subjective or objective measures of lameness in horses with chronic thoracic limb musculoskeletal pain. Although subjective evaluation identified an improvement in lameness with treatment GF, it was not different from that observed with treatment F. Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses.",

keywords = "equine chronic lameness, firocoxib, gabapentin, pain management",

author = "Young, \{Jenna M.\} and Schoonover, \{Mike J.\} and Kembel, \{S. Logan\} and Taylor, \{Jared D.\} and Bauck, \{Anje G.\} and Gilliam, \{Lyndi L.\}",

note = "Funding Information: Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee , OK, USA. The firocoxib tablets were provided by Merial Inc., GA, USA. Funding Information: Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee, OK, USA. The firocoxib tablets were provided by Merial Inc. GA, USA. Publisher Copyright: {\textcopyright} 2019 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia",

year = "2020",

month = mar,

doi = "10.1016/j.vaa.2019.11.003",

language = "English (US)",

volume = "47",

pages = "259--266",

journal = "Veterinary anaesthesia and analgesia",

issn = "1467-2987",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness

AU - Young, Jenna M.

AU - Schoonover, Mike J.

AU - Kembel, S. Logan

AU - Taylor, Jared D.

AU - Bauck, Anje G.

AU - Gilliam, Lyndi L.

N1 - Funding Information: Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee , OK, USA. The firocoxib tablets were provided by Merial Inc., GA, USA. Funding Information: Funding for this project was provided by the Oklahoma State University, College of Veterinary Medicine, Research Advisory Committee, OK, USA. The firocoxib tablets were provided by Merial Inc. GA, USA. Publisher Copyright: © 2019 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia

PY - 2020/3

Y1 - 2020/3

N2 - Objective: To evaluate the analgesic effects of orally administered gabapentin on horses with chronic thoracic limb lameness. Study design: Randomized, crossover design. Animals: A total of 14 adult horses with chronic thoracic limb lameness. Methods: Following baseline measurement of lameness, horses were administered each of four treatments orally in grain: treatment G, gabapentin (20 mg kg–1) twice daily for 13 doses; treatment F, firocoxib (171 mg once, then 57 mg once daily for six doses); treatment GF, gabapentin and firocoxib at previously stated doses and frequencies; or treatment C, grain only as a control. Treatments were administered in a randomized, crossover design, separated by 2 weeks. Subjective lameness score (SLS), inertial sensor vector sum (VS) calculations, peak vertical ground reaction force (PVGRF) measurements and vertical impulse (VI) calculations were determined immediately prior to each initial treatment dose and 2–4 hours after the final treatment dose for each treatment. Mean change in SLS, VS, PVGRF and VI for each treatment were compared among treatments. Results: The rank change in SLS of treatment GF was significantly greater than that of treatments C (p = 0.01) and G (p = 0.01) but not of treatment F (p = 0.08). No differences in VS (p = 0.4), PVGRF (p = 0.4) or VI (p = 0.1) were observed among treatments. Conclusions and clinical relevance: Gabapentin, as administered here, did not improve subjective or objective measures of lameness in horses with chronic thoracic limb musculoskeletal pain. Although subjective evaluation identified an improvement in lameness with treatment GF, it was not different from that observed with treatment F. Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses.

AB - Objective: To evaluate the analgesic effects of orally administered gabapentin on horses with chronic thoracic limb lameness. Study design: Randomized, crossover design. Animals: A total of 14 adult horses with chronic thoracic limb lameness. Methods: Following baseline measurement of lameness, horses were administered each of four treatments orally in grain: treatment G, gabapentin (20 mg kg–1) twice daily for 13 doses; treatment F, firocoxib (171 mg once, then 57 mg once daily for six doses); treatment GF, gabapentin and firocoxib at previously stated doses and frequencies; or treatment C, grain only as a control. Treatments were administered in a randomized, crossover design, separated by 2 weeks. Subjective lameness score (SLS), inertial sensor vector sum (VS) calculations, peak vertical ground reaction force (PVGRF) measurements and vertical impulse (VI) calculations were determined immediately prior to each initial treatment dose and 2–4 hours after the final treatment dose for each treatment. Mean change in SLS, VS, PVGRF and VI for each treatment were compared among treatments. Results: The rank change in SLS of treatment GF was significantly greater than that of treatments C (p = 0.01) and G (p = 0.01) but not of treatment F (p = 0.08). No differences in VS (p = 0.4), PVGRF (p = 0.4) or VI (p = 0.1) were observed among treatments. Conclusions and clinical relevance: Gabapentin, as administered here, did not improve subjective or objective measures of lameness in horses with chronic thoracic limb musculoskeletal pain. Although subjective evaluation identified an improvement in lameness with treatment GF, it was not different from that observed with treatment F. Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses.

KW - equine chronic lameness

KW - firocoxib

KW - gabapentin

KW - pain management

UR - https://www.scopus.com/pages/publications/85078610670

UR - https://www.scopus.com/pages/publications/85078610670#tab=citedBy

U2 - 10.1016/j.vaa.2019.11.003

DO - 10.1016/j.vaa.2019.11.003

M3 - Article

C2 - 31980368

AN - SCOPUS:85078610670

SN - 1467-2987

VL - 47

SP - 259

EP - 266

JO - Veterinary anaesthesia and analgesia

JF - Veterinary anaesthesia and analgesia

IS - 2

ER -

Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this